Premium
Bromocriptine (Parlodel) for Suppression of Lactation
Author(s) -
Spalding Gordon
Publication year - 1991
Publication title -
australian and new zealand journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.734
H-Index - 65
eISSN - 1479-828X
pISSN - 0004-8666
DOI - 10.1111/j.1479-828x.1991.tb02817.x
Subject(s) - bromocriptine , lactation , medicine , tamoxifen , gynecology , obstetrics , prolactin , breast cancer , pregnancy , hormone , cancer , biology , genetics
EDITORIAL COMMENT: This pharmacology comment is published to inform readers of possible complications of bromocriptine therapy and to remind them that most women who elect not to breast‐feed do not require drug therapy to suppress lactation, especially if breast‐feeding has not been attempted. As noted in a previous comment (IA), suppression of lactation by oestrogen therapy was discontinued 24 years ago when it was found to be associated with thromboembolism. We then realized how few women were troubled by severe breast engorgement. Opinion has hardened against the routine use of drug therapy for inhibition of ‘physiological’ lactation